Inspiration for PathoLase
Inspiration for PathoLase and its therapies was borne out of the founder’s desire to help his young daughter, Jessica (August 23, 1991—March 26, 2008), suffering from end–stage respiratory failure that required a double live lobar (lung) transplant. PathoLase’s founder, John Strisower, theorized that respiratory viral, bacterial, fungal and mold related diseases could be treated with germicidal light using innovative delivery systems and procedures.
This concept spawned a new generation of research into the most efficient germicidal agent—light. By applying technological advances in lasers, fiber optic delivery systems and computer controllers, PathoLase is proving that the healing force of light can be introduced into the human body—promising a range of medical treatments from head to toe. These therapies are being developed for diseases caused by pathogens in bodily cavities, fluids and external infections.
The PinPointe FootLaser™* Story
In 2006, after PathoLase identified the need for a light‐based protocol for onychomycosis (nail fungus), Founder, John Strisower, gathered around him an expert team who started with the basic science and research, math modeling and clinical dosimetry.
In 2008, PathoLase built the first prototype of the PinPointe™ FootLaser™ and began multi‐phase clinical trials, later submitting results to the FDA and global regulatory bodies for clearance. The FootLaser became the first cleared global market leader for devices of its kind with clinically‐proven results.
In September of 2011, the PinPointe FootLaser product line was spun out to (NuvoLase, Inc.) and in October of 2011, (Cynosure, Inc. NASD: CYNO) announced its acquisition of worldwide exclusive distribution rights of the PinPointe FootLaser from NuvoLase.
* PinPointe FootLaser is a registered trademark of NuvoLase Inc.
Leave a Reply